Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy

British Journal of Clinical Pharmacology

Volumn 67, Issue 2, 2009, Pages 234-241

  Devold, Helene M ^a,b   Molden, Espen ^b   Skurtveit, Svetlana ^a,c   Furu, Kari ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

CYP3A4; Drug interactions; HMG CoA reductase inhibitors; Reimbursement; Simvastatin

Indexed keywords

AMIODARONE; ANTIFUNGAL AGENT; ATORVASTATIN; CLARITHROMYCIN; CYTOCHROME P450 3A4 INHIBITOR; CYTOCHROME P450 INHIBITOR; DILTIAZEM; ERYTHROMYCIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; PROTEINASE INHIBITOR; SIMVASTATIN; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; DRUG CROSS REACTIVITY; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; ENZYME KINETICS; HUMAN; MUSCLE DISEASE; NORWAY; PRIORITY JOURNAL; REIMBURSEMENT; RHABDOMYOLYSIS;

ANTICHOLESTEREMIC AGENTS; COMBINED MODALITY THERAPY; CYTOCHROME P-450 CYP3A; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NORWAY; PHYSICIAN'S PRACTICE PATTERNS; REIMBURSEMENT MECHANISMS; SIMVASTATIN;

EID: 61349195721     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03345.x     Document Type: Article

References (33)

1. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, Pyorala K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel H. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) 1994. Atheroscler Suppl 2004 5 : 81 7.
2. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004 363 : 757 67.
3. Larosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 352 : 1425 35.
4. Maggini M, Raschetti R, Traversa G, Bianchi C, Caffari B, Da Cas R, Panei P. The cerivastatin withdrawal crisis: a 'post-mortem' analysis. Health Policy 2004 69 : 151 7.
5. Armitage J. The safety of statins in clinical practice. Lancet 2007 370 : 1781 90.
6. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004 292 : 2585 90.
7. Mukhtar RY, Reckless JP. Statin-induced myositis: a commonly encountered or rare side effect? Curr Opin Lipidol 2005 16 : 640 7.
8. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002 36 : 288 95.
9. Pasternak RC, Smith SC Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 2002 33 : 2337 41.
10. Ronaldson KJ, O'Shea JM, Boyd IW. Risk factors for rhabdomyolysis with simvastatin and atorvastatin. Drug Saf 2006 29 : 1061 7.
11. Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, Burgess M, Blough D, Stergachis A, Chan KA, Platt R, Shatin D. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2007 16 : 352 8.
12. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JP, Stein EA. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003 163 : 553 64.
13. Molden E. Variability in cytochrome P450-mediated metabolism of cardiovascular drugs: clinical implications and practical attempts to avoid potential problems. Heart Drug 2004 4 : 55 79.
14. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004 94 : 1140 6.
15. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006 80 : 565 81.
16. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, Gandhi P. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007 29 : 253 60.
17. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005 60 : 543 51.
18. Refusjon: Statiner-Nye Vilkår For Refusjon (in English: Statins-New Reimbursement Regulations). Oslo : Norwegian Medicines Agency. 13-4-2005. Ref Type: Electronic Citation.
19. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998 64 : 177 82.
20. Tobi H, Faber A, Van Den Berg PB, Drane JW, De Jong-Van Den Berg LT. Studying co-medication patterns: the impact of definitions. Pharmacoepidemiol Drug Saf 2007 16 : 405 11.
21. Sakshaug S, Furu K, Karlstad O, Ronning M, Skurtveit S. Switching statins in Norway after new reimbursement policy: a nationwide prescription study. Br J Clin Pharmacol 2007 64 : 476 81.
22. Molden E, Westergren T Interaction risk with statin switch Tidsskr Nor Laegeforen 2007 127 : 428 31.
23. Heerey A, Barry M, Ryan M, Kelly A. The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 2000 169 : 176 9.
24. Einarson TR, Metge CJ, Iskedjian M, Mukherjee J. An examination of the effect of cytochrome p450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther 2002 24 : 2126 36.
25. Teeling M, Bennett K, Feely J. The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002. Br J Clin Pharmacol 2005 59 : 227 32.
26. Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - New opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi 2008 18 : 129 36.
27. Wettermark B, Hammar N, Michaelfored C, Leimanis A, Otterblad OP, Bergman U, Persson I, Sundstrom A, Westerholm B, Rosen M. The new Swedish prescribed drug register - opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007 16 : 726 35.
28. Williams D, Bennett K, Feely J. The application of prescribing indicators to a primary care prescription database in Ireland. Eur J Clin Pharmacol 2005 61 : 127 33.
29. Bottorff MB. Statin safety and drug interactions: clinical implications. [Review Am J Cardiol 2006 97 : 27C 31C.
30. Cziraky MJ, Willey VJ, Mckenney JM, Kamat SA, Fisher MD, Guyton JR, Jacobson TA, Davidson MH. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006 97 : 61C 8C.
31. Summary of product characteristics zocor. Available at http://www.legemiddelverket.no/spc/godkjente/zocor-no-spc-godkj-mai03.doc (last accessed 14 November 2006). Ref Type: Electronic Citation.
32. Egger SS, Ratz Bravo AE, Hess L, Schlienger RG, Krahenbuhl S. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 2007 24 : 429 40.
33. Raffel OC, White HD. Drug insight: statin use in the elderly. Nat Clin Pract Cardiovasc Med 2006 3 : 318 28.